AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Journal of Neurorestoratology Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Magnesium ions and dementia

Pei Xua, Dehua Cuib( ), Mingyue Jina( ), Liyuan Suna( )
Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin 541199, Guangxi, China
Beijing Key Laboratory of Magnetic Resonance Imaging Devices and Technology and Department of Neurology, Peking University Third Hospital, Beijing 100191, China
Show Author Information

Abstract

Magnesium is an essential nutrient involved in a wide range of physiological activities to maintain normal brain functions. So far, magnesium has been recognized as a cofactor for over 600 enzymatic reactions within the body. Importantly, magnesium deficiency has been implicated in the pathogenesis of various dementia-related diseases containing cardiovascular diseases and Alzheimer’s disease (AD). With increased aging, the incidence and prevalence of dementia are expected to rise dramatically double every 20 years worldwide. Accumulating evidence indicates that dementia-related diseases are associated with low magnesium levels, and dietary magnesium intake can improve cognitive function. Many studies have revealed that magnesium ions act as a natural Ca2+ blocker to inhibit calcium overload and halt the course of AD by blocking N-methyl-D-aspartate receptors and thus inhibiting neuronal overactivation. In addition, magnesium ions can inhibit glial cell-mediated neuroinflammation by down-regulating pro-inflammatory cytokines and oxidative stress, which have been implicated in the development of chronic age-related diseases. Thus, magnesium may be a target for the prevention and treatment of neurological diseases. Taken together, maintaining an optimal magnesium balance may help in the prevention of cognitive decline and dementia. In this review, we summarize our current understanding of the role of magnesium in dementia, highlighting recent progresses in the field.

Keywords

MagnesiumVascular dementiaAlzheimer's diseaseDementia

References

1

Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–2117. https://doi.org/10.1016/s0140-6736(05)67889-0.
Crossref Google Scholar
2

Li G, Shen YC, Chen CH, et al. An epidemiological survey of age-related dementia in an urban area of Beijing. Acta Psychiatr Scand. 1989;79(6):557–563. https://doi.org/10.1111/j.1600-0447.1989.tb10303.x.
Crossref Google Scholar
3

Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol. 2009;66(3):343–348. https://doi.org/10.1001/archneur.66.3.343.
Crossref Google Scholar
4

Skoog I. Status of risk factors for vascular dementia. Neuroepidemiology. 1998;17(1):2–9. https://doi.org/10.1159/000026147.
Crossref Google Scholar
5

Davey DA. Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: pathology, diagnosis and screening. Neurodegener Dis Manag. 2014;4(3):253–259. https://doi.org/10.2217/nmt.14.14.
Crossref Google Scholar
6

Reddy ST, Soman SS, Yee J. Magnesium balance and measurement. Adv Chron Kidney Dis. 2018;25(3):224–229. https://doi.org/10.1053/j.ackd.2018. 03.002.
Crossref Google Scholar
7

Ventskivs’ka IB, Senchuk AI. Role of magnesium in the pathogenesis of premenstrual disorders. Lik Sprava. 2005;(8):62–65.
Google Scholar
8

Barbagallo M, Veronese N, Dominguez LJ. Magnesium in aging, health and diseases. Nutrients. 2021;13(2):463. https://doi.org/10.3390/nu13020463.
Crossref Google Scholar
9

Muir KW. Magnesium in stroke treatment. Postgrad Med. 2002;78(925):641–645. https://doi.org/10.1136/pmj.78.925.641.
Crossref Google Scholar
10

Rinösl H, Skhirtladze K, Felli A, et al. The neuroprotective effect of magnesium sulphate during iatrogenically-induced ventricular fibrillation. Magnes Res. 2013;26(3):109–119. https://doi.org/10.1684/mrh.2013.0345.
Crossref Google Scholar
11

Afshari D, Moradian N, Rezaei M. Evaluation of the intravenous magnesium sulfate effect in clinical improvement of patients with acute ischemic stroke. Clin Neurol Neurosurg. 2013;115(4):400–404. https://doi.org/10.1016/j.clineuro.2012.06.001.
Crossref Google Scholar
12

Lou Z, Ren KD, Tan B, et al. Salviaolate protects rat brain from ischemia-reperfusion injury through inhibition of NADPH oxidase. Planta Med. 2015;81(15):1361–1369. https://doi.org/10.1055/s-0035-1557774.
Crossref Google Scholar
13

Clerc P, Young CA, Bordt EA, et al. Magnesium sulfate protects against the bioenergetic consequences of chronic glutamate receptor stimulation. PLoS One. 2013;8(11):e79982. https://doi.org/10.1371/journal.pone.0079982.
Crossref Google Scholar
14

Wang P, Yu X, Guan PP, et al. Magnesium ion influx reduces neuroinflammation in Aβ precursor protein/Presenilin 1 transgenic mice by suppressing the expression of interleukin-1β. Cell Mol Immunol. 2017;14(5):451–464. https://doi.org/10.1038/cmi.2015.93.
Crossref Google Scholar
15

Veronese N, Zurlo A, Solmi M, et al. Magnesium status in Alzheimer's disease: a systematic review. Am J Alzheimers Dis Other Demen. 2016;31(3):208–213. https://doi.org/10.1177/1533317515602674.
Crossref Google Scholar
16

Wilmott LA, Thompson LT. Sex- and dose-dependent effects of post-trial calcium channel blockade by magnesium chloride on memory for inhibitory avoidance conditioning. Behav Brain Res. 2013;257:49–53. https://doi.org/10.1016/j.bbr.2013.09.047.
Crossref Google Scholar
17

Lamhot VB, Khatib N, Ginsberg Y, et al. Magnesium sulfate prevents maternal inflammation-induced impairment of learning ability and memory in rat offspring. Am J Obstet Gynecol. 2015;213(6):851. https://doi.org/10.1016/j.ajog.2015.07.042.e1-8.
Crossref Google Scholar
18

Slutsky I, Abumaria N, Wu LJ, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010;65(2):165–177. https://doi.org/10.1016/j.neuron.2009.12.026.
Crossref Google Scholar
19

Abumaria N, Yin B, Zhang L, et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci. 2011;31(42):14871–14881. https://doi.org/10.1523/jneurosci.3782-11.2011.
Crossref Google Scholar
20

Bardgett ME, Schultheis PJ, McGill DL, et al. Magnesium deficiency impairs fear conditioning in mice. Brain Res. 2005;1038(1):100–106. https://doi.org/10.1016/j.brainres.2005.01.020.
Crossref Google Scholar
21

Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatr. 2003;18(suppl 1):S23–S32. https://doi.org/10.1002/gps.938.
Crossref Google Scholar
22

Ozturk S, Cillier AE. Magnesium supplementation in the treatment of dementia patients. Med Hypotheses. 2006;67(5):1223–1225. https://doi.org/10.1016/j.mehy.2006.04.047.
Crossref Google Scholar
23

Kirkland AE, Sarlo GL, Holton KF. The role of magnesium in neurological disorders. Nutrients. 2018;10(6):730. https://doi.org/10.3390/nu100 60730.
Crossref Google Scholar
24

Yasui M, Ota K. Serum concentrations of magnesium and parathyroid hormone in randomly selected hospital in-patients and out-patients, and in in-patients with dementia. J Int Med Res. 1992;20(4):313–322. https://doi.org/10.1177/030006059202000402.
Crossref Google Scholar
25

Bayer KU, De Koninck P, Leonard AS, et al. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature. 2001;411(6839):801–805. https://doi.org/10.1038/35081080.
Crossref Google Scholar
26

Bayer KU, LeBel E, McDonald GL, et al. Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci. 2006;26(4):1164–1174. https://doi.org/10.1523/jneurosci.3116-05.2006.
Crossref Google Scholar
27

Bi H, Sze CI. N-methyl-D-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer's disease. J Neurol Sci. 2002;200(1/2):11–18. https://doi.org/10.1016/s0022-510x(02)00087-4.
Crossref Google Scholar
28

Gaffney-Stomberg E. The impact of trace minerals on bone metabolism. Biol Trace Elem Res. 2019;188(1):26–34. https://doi.org/10.1007/s12011-018-1583-8.
Crossref Google Scholar
29

Andrási E, Igaz S, Molnár Z, et al. Disturbances of magnesium concentrations in various brain areas in Alzheimer's disease. Magnes Res. 2000;13(3):189–196.
Google Scholar
30

Borella P, Giardino A, Neri M, et al. Magnesium and potassium status in elderly subjects with and without dementia of the Alzheimer type. Magnes Res. 1990;3(4):283–289.
Google Scholar
31

Cilliler AE, Ozturk S, Ozbakir S. Serum magnesium level and clinical deterioration in Alzheimer's disease. Gerontology. 2007;53(6):419–422. https://doi.org/10.1159/000110873.
Crossref Google Scholar
32

Gerhardsson L, Blennow K, Lundh T, et al. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2009;28(1):88–94. https://doi.org/10.1159/000233353.
Crossref Google Scholar
33

Gerhardsson L, Lundh T, Minthon L, et al. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2008;25(6):508–515. https://doi.org/10.1159/000129365.
Crossref Google Scholar
34

Basun H, Forssell LG, Wetterberg L, et al. Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect. 1991;3(4):231–258.
Google Scholar
35

Babić Leko M, Mihelčić M, Jurasović J, et al. Heavy metals and essential metals are associated with cerebrospinal fluid biomarkers of Alzheimer's disease. Int J Mol Sci. 2022;24(1):467. https://doi.org/10.3390/ijms24010467.
Crossref Google Scholar
36

Deane R, Yan SD, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9(7):907–913. https://doi.org/10.1038/nm890.
Crossref Google Scholar
37

Deane R, Wu ZH, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43(3):333–344. https://doi.org/10.1016/j.neuron.2004.07.017.
Crossref Google Scholar
38

Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106(12):1489–1499. https://doi.org/10.1172/jci10498.
Crossref Google Scholar
39

Kanekiyo T, Liu CC, Shinohara M, et al. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-B. J Neurosci. 2012;32(46):16458–16465. https://doi.org/10.1523/jneurosci.3987-12.2012.
Crossref Google Scholar
40

Zhu DH, Su YC, Fu BM, et al. Magnesium reduces blood-brain barrier permeability and regulates amyloid-β transcytosis. Mol Neurobiol. 2018;55(9):7118–7131. https://doi.org/10.1007/s12035-018-0896-0.
Crossref Google Scholar
41

Yu J, Sun M, Chen Z, et al. Magnesium modulates amyloid-beta protein precursor trafficking and processing. J Alzheimers Dis. 2010;20(4):1091–1106. https://doi.org/10.3233/jad-2010-091444.
Crossref Google Scholar
42

De Reuck J, Decoo D, Marchau M, et al. Positron emission tomography in vascular dementia. J Neurol Sci. 1998;154(1):55–61. https://doi.org/10.1016/s0022-510x(97)00213-x.
Crossref Google Scholar
43

Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844–866. https://doi.org/10.1016/j.neuron.2013.10.008.
Crossref Google Scholar
44

Shabir O, Berwick J, Francis SE. Neurovascular dysfunction in vascular dementia, Alzheimer's and atherosclerosis. BMC Neurosci. 2018;19(1):62. https://doi.org/10.1186/s12868-018-0465-5.
Crossref Google Scholar
45

van den Bergh WM, Zuur JK, Kamerling NA, et al. Role of magnesium in the reduction of ischemic depolarization and lesion volume after experimental subarachnoid hemorrhage. J Neurosurg. 2002;97(2):416–422. https://doi.org/10.3171/jns.2002.97.2.0416.
Crossref Google Scholar
46

Nowak L, Bregestovski P, Ascher P, et al. Magnesium gates glutamate-activated channels in mouse central neurones. Nature. 1984;307(5950):462–465. https://doi.org/10.1038/307462a0.
Crossref Google Scholar
47

Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 1998;11(9):523–569. https://doi.org/10.1358/dnp.1998.11.9.863689.
Crossref Google Scholar
48

Doraiswamy PM. Alzheimer's disease and the glutamate NMDA receptor. Psychopharmacol Bull. 2003;37(2):41–49.
Google Scholar
49

Jain KK. Evaluation of memantine for neuroprotection in dementia. Expet Opin Invest Drugs. 2000;9(6):1397–1406. https://doi.org/10.1517/13543784.9.6.1397.
Crossref Google Scholar
50

Gao J, Duan B, Wang DG, et al. Coupling between NMDA receptor and acid-sensing ion channel contributes to ischemic neuronal death. Neuron. 2005;48(4):635–646. https://doi.org/10.1016/j.neuron.2005.10.011.
Crossref Google Scholar
51

Barria A, Malinow R. NMDA receptor subunit composition controls synaptic plasticity by regulating binding to CaMKII. Neuron. 2005;48(2):289–301. https://doi.org/10.1016/j.neuron.2005.08.034.
Crossref Google Scholar
52

Kass IS, Cottrell JE, Chambers G. Magnesium and cobalt, not nimodipine, protect neurons against anoxic damage in the rat hippocampal slice. Anesthesiology. 1988;69(5):710–715. https://doi.org/10.1097/00000542-198811000-00012.
Crossref Google Scholar
53

Vener AV, Aksenova MV, Burbaeva GS. Drastic reduction of the zinc- and magnesium-stimulated protein tyrosine kinase activities in Alzheimer's disease hippocampus. FEBS Lett. 1993;328(1/2):6–8. https://doi.org/10.1016/0014-5793(93)80953-r.
Crossref Google Scholar
54

Malchiodi-Albedi F, Paradisi S, Matteucci A, et al. Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. Int J Alzheimer's Dis. 2011;2011: 906964. https://doi.org/10.4061/2011/906964.
Crossref Google Scholar
55

Schilling T, Eder C. Amyloid-β-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia. J Cell Physiol. 2011;226(12):3295–3302. https://doi.org/10.1002/jcp.22675.
Crossref Google Scholar
56

Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium. 2003;34(4/5):385–397. https://doi.org/10.1016/s0143-4160(03)00128-3.
Crossref Google Scholar
57

Gao F, Ding BZ, Zhou LA, et al. Magnesium sulfate provides neuroprotection in lipopolysaccharide-activated primary microglia by inhibiting NF-κB pathway. J Surg Res. 2013;184(2):944–950. https://doi.org/10.1016/j.jss.2013.03.034.
Crossref Google Scholar
58

Nagele RG, D'Andrea MR, Lee H, et al. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003;971(2):197–209. https://doi.org/10.1016/s0006-8993(03)02361-8.
Crossref Google Scholar
59

Town T, Nikolic V, Tan J. The microglial “activation” continuum: from innate to adaptive responses. J Neuroinflammation. 2005;2:24. https://doi.org/10.1186/1742-2094-2-24.
Crossref Google Scholar
60

Yamamoto M, Kiyota T, Horiba M, et al. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol. 2007;170(2):680–692. https://doi.org/10.2353/ajpath.2007.060378.
Crossref Google Scholar
61

Liao YF, Wang BJ, Cheng HT, et al. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem. 2004;279(47):49523–49532. https://doi.org/10.1074/jbc.M402034200.
Crossref Google Scholar
62

Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008;28(33):8354–8360. https://doi.org/10.1523/jneurosci.0616-08.2008.
Crossref Google Scholar
63

Kitazawa M, Cheng D, Tsukamoto MR, et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol. 2011;187(12):6539–6549. https://doi.org/10.4049/jimmunol.1100620.
Crossref Google Scholar
64

Rochelson B, Dowling O, Schwartz N, et al. Magnesium sulfate suppresses inflammatory responses by human umbilical vein endothelial cells (HuVECs) through the NFκB pathway. J Reprod Immunol. 2007;73(2):101–107. https://doi.org/10.1016/j.jri.2006.06.004.
Crossref Google Scholar
65

Li XL, Liu HS, Yang YY. Magnesium sulfate attenuates brain edema by lowering AQP4 expression and inhibits glia-mediated neuroinflammation in a rodent model of eclampsia. Behav Brain Res. 2019;364:403–412. https://doi.org/10.1016/j.bbr.2017.12.031.
Crossref Google Scholar
66

Andrási E, Páli N, Molnár Z, et al. Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. J Alzheimers Dis. 2005;7(4):273–284. https://doi.org/10.3233/jad-2005-7402.
Crossref Google Scholar
67

Atabek ME, Kurtoglu S, Pirgon O, et al. Serum magnesium concentrations in type 1 diabetic patients: relation to early atherosclerosis. Diabetes Res Clin Pract. 2006;72(1):42–47. https://doi.org/10.1016/j.diabres.2005.09.002.
Crossref Google Scholar
68

Sinclair AJ, Bayer AJ, Johnston J, et al. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatr. 1998;13(12):840–845. https://doi.org/10.1002/(sici)1099-1166(1998120)13:12<840::aid-gps877>3.0.co;2-r.
Crossref Google Scholar
69

Garcia LA, Dejong SC, Martin SM, et al. Magnesium reduces free radicals in an in vivo coronary occlusion-reperfusion model. J Am Coll Cardiol. 1998;32(2):536–539. https://doi.org/10.1016/s0735-1097(98)00231-9.
Crossref Google Scholar
70

Regan RF, Jasper E, Guo Y, et al. The effect of magnesium on oxidative neuronal injury in vitro. J Neurochem. 1998;70(1):77–85. https://doi.org/10.1046/j.1471-4159.1998.70010077.x.
Crossref Google Scholar
71

Back SA, Kroenke CD, Sherman LS, et al. White matter lesions defined by diffusion tensor imaging in older adults. Ann Neurol. 2011;70(3):465–476. https://doi.org/10.1002/ana.22484.
Crossref Google Scholar
72

Kaiser D, Weise GS, Möller K, et al. Spontaneous white matter damage, cognitive decline and neuroinflammation in middle-aged hypertensive rats: an animal model of early-stage cerebral small vessel disease. Acta Neuropathol Commun. 2014;2:169. https://doi.org/10.1186/s40478-014-0169-8.
Crossref Google Scholar
73

Metti AL, Yaffe K, Boudreau RM, et al. Trajectories of inflammatory markers and cognitive decline over 10 years. Neurobiol Aging. 2014;35(12):2785–2790. https://doi.org/10.1016/j.neurobiolaging.2014.05.030.
Crossref Google Scholar
74

Crehan H, Hardy J, Pocock J. Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis. 2013;54:139–149. https://doi.org/10.1016/j.nbd.2013.02.003.
Crossref Google Scholar
75

Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34(1):43–62. https://doi.org/10.1007/s00281-011-0290-8.
Crossref Google Scholar
76

Cohen RA, Tong XY. Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease. J Cardiovasc Pharmacol. 2010;55(4):308–316. https://doi.org/10.1097/fjc.0b013e3181d89670.
Crossref Google Scholar
77

Xu RS. Pathogenesis of diabetic cerebral vascular disease complication. World J Diabetes. 2015;6(1):54–66. https://doi.org/10.4239/wjd.v6.i1.54.
Crossref Google Scholar
78

Belin RJ, He K. Magnesium physiology and pathogenic mechanisms that contribute to the development of the metabolic syndrome. Magnes Res. 2007;20(2):107–129.
Google Scholar
79

Luo JJ, Lan HW, Jiang JJ, et al. Effect of magnesium L-threonate on chronic cerebral hypoperfusion-induced cerebral white matter injury in patients. Chin J Hematol. 2022;35(5):8–12. https://doi.org/10.19296/j.cnki.1008-2409.2022-05-002.
Crossref Google Scholar
80

de Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95(1):1–46. https://doi.org/10.1152/physrev.00012.2014.
Crossref Google Scholar
81

Okumoto Y, Koyama E, Matsubara H, et al. Sleep improvement by light in a demented aged individual. Psychiatr Clin Neurosci. 1998;52(2):194–196. https://doi.org/10.1111/j.1440-1819.1998.tb01026.x.
Crossref Google Scholar
82

You HJ, Cho SE, Kang SG, et al. Decreased serum magnesium levels in depression: a systematic review and meta-analysis. Nord J Psychiatr. 2018;72(7):534–541. https://doi.org/10.1080/08039488.2018.1538388.
Crossref Google Scholar
83

Botturi A, Ciappolino V, Delvecchio G, et al. The role and the effect of magnesium in mental disorders: a systematic review. Nutrients. 2020;12(6):1661. https://doi.org/10.3390/nu12061661.
Crossref Google Scholar
84

Phelan D, Molero P, Martínez-González MA, et al. Magnesium and mood disorders: systematic review and meta-analysis. BJPsych Open. 2018;4(4):167–179. https://doi.org/10.1192/bjo.2018.22.
Crossref Google Scholar
85

Sanders O, Rajagopal L. Phosphodiesterase inhibitors for Alzheimer's disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale. J Alzheimers Dis Rep. 2020;4(1):185–215. https://doi.org/10.3233/ADR-200191.
Crossref Google Scholar
86

Zhao X, Liu J, Yang S, et al. A novel pharmacodynamic model in rats for preventing vascular dementia from maintaining neurovascular coupling sensitivity. Eur J Pharmacol. 2018;827:149–158. https://doi.org/10.1016/j.ejphar.2018.03.010.
Crossref Google Scholar
87

Okada M, Kaneko S. Pharmacological interactions between magnesium ion and adenosine on monoaminergic system in the central nervous system. Magnes Res. 1998;11(4):289–305.
Google Scholar
88

Iotti S, Malucelli E. In vivo assessment of Mg2+ in human brain and skeletal muscle by 31P-MRS. Magnes Res. 2008;21(3):157–162.
Google Scholar
Journal of Neurorestoratology
Volume 12 Issue 1,
March 2024
Article number: 100094
DOI: 10.1016/j.jnrt.2024.100094
Cite this article:
Xu P, Cui D, Jin M, et al. Magnesium ions and dementia. Journal of Neurorestoratology, 2024, 12(1): 100094. https://doi.org/10.1016/j.jnrt.2024.100094

577

Views

1

Crossref

2

Web of Science

1

Scopus

Altmetrics
Received: 12 July 2023
Revised: 28 November 2023
Accepted: 25 December 2023
Published: 12 January 2024
© 2024.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Return